These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3545 related articles for article (PubMed ID: 18539916)

  • 1. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    ; Patel A; MacMahon S; Chalmers J; Neal B; Billot L; Woodward M; Marre M; Cooper M; Glasziou P; Grobbee D; Hamet P; Harrap S; Heller S; Liu L; Mancia G; Mogensen CE; Pan C; Poulter N; Rodgers A; Williams B; Bompoint S; de Galan BE; Joshi R; Travert F
    N Engl J Med; 2008 Jun; 358(24):2560-72. PubMed ID: 18539916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucose control and vascular complications in veterans with type 2 diabetes.
    Duckworth W; Abraira C; Moritz T; Reda D; Emanuele N; Reaven PD; Zieve FJ; Marks J; Davis SN; Hayward R; Warren SR; Goldman S; McCarren M; Vitek ME; Henderson WG; Huang GD;
    N Engl J Med; 2009 Jan; 360(2):129-39. PubMed ID: 19092145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of intensive glucose lowering in type 2 diabetes.
    ; Gerstein HC; Miller ME; Byington RP; Goff DC; Bigger JT; Buse JB; Cushman WC; Genuth S; Ismail-Beigi F; Grimm RH; Probstfield JL; Simons-Morton DG; Friedewald WT
    N Engl J Med; 2008 Jun; 358(24):2545-59. PubMed ID: 18539917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of intensive glucose lowering on cardiovascular outcomes.
    ; Gerstein HC; Miller ME; Genuth S; Ismail-Beigi F; Buse JB; Goff DC; Probstfield JL; Cushman WC; Ginsberg HN; Bigger JT; Grimm RH; Byington RP; Rosenberg YD; Friedewald WT
    N Engl J Med; 2011 Mar; 364(9):818-28. PubMed ID: 21366473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe hypoglycemia and risks of vascular events and death.
    Zoungas S; Patel A; Chalmers J; de Galan BE; Li Q; Billot L; Woodward M; Ninomiya T; Neal B; MacMahon S; Grobbee DE; Kengne AP; Marre M; Heller S;
    N Engl J Med; 2010 Oct; 363(15):1410-8. PubMed ID: 20925543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.
    Zoungas S; Chalmers J; Neal B; Billot L; Li Q; Hirakawa Y; Arima H; Monaghan H; Joshi R; Colagiuri S; Cooper ME; Glasziou P; Grobbee D; Hamet P; Harrap S; Heller S; Lisheng L; Mancia G; Marre M; Matthews DR; Mogensen CE; Perkovic V; Poulter N; Rodgers A; Williams B; MacMahon S; Patel A; Woodward M;
    N Engl J Med; 2014 Oct; 371(15):1392-406. PubMed ID: 25234206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive Glucose Control in Patients with Type 2 Diabetes - 15-Year Follow-up.
    Reaven PD; Emanuele NV; Wiitala WL; Bahn GD; Reda DJ; McCarren M; Duckworth WC; Hayward RA;
    N Engl J Med; 2019 Jun; 380(23):2215-2224. PubMed ID: 31167051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycaemic control and macrovascular and microvascular outcomes: A systematic review and meta-analysis of trials investigating intensive glucose-lowering strategies in people with type 2 diabetes.
    Kunutsor SK; Balasubramanian VG; Zaccardi F; Gillies CL; Aroda VR; Seidu S; Khunti K
    Diabetes Obes Metab; 2024 Jun; 26(6):2069-2081. PubMed ID: 38409644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes.
    Hayward RA; Reaven PD; Wiitala WL; Bahn GD; Reda DJ; Ge L; McCarren M; Duckworth WC; Emanuele NV;
    N Engl J Med; 2015 Jun; 372(23):2197-206. PubMed ID: 26039600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.
    Ismail-Beigi F; Craven T; Banerji MA; Basile J; Calles J; Cohen RM; Cuddihy R; Cushman WC; Genuth S; Grimm RH; Hamilton BP; Hoogwerf B; Karl D; Katz L; Krikorian A; O'Connor P; Pop-Busui R; Schubart U; Simmons D; Taylor H; Thomas A; Weiss D; Hramiak I;
    Lancet; 2010 Aug; 376(9739):419-30. PubMed ID: 20594588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial.
    Woodward M; Patel A; Zoungas S; Liu L; Pan C; Poulter N; Januszewicz A; Tandon N; Joshi P; Heller S; Neal B; Chalmers J
    Diabetes Care; 2011 Dec; 34(12):2491-5. PubMed ID: 21972410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation.
    J Hypertens Suppl; 2001 Nov; 19(4):S21-8. PubMed ID: 11848259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a multicomponent quality improvement strategy on sustained achievement of diabetes care goals and macrovascular and microvascular complications in South Asia at 6.5 years follow-up: Post hoc analyses of the CARRS randomized clinical trial.
    Ali MK; Singh K; Kondal D; Devarajan R; Patel SA; Menon VU; Varthakavi PK; Vishwanathan V; Dharmalingam M; Bantwal G; Sahay RK; Masood MQ; Khadgawat R; Desai A; Prabhakaran D; Narayan KMV; Tandon N
    PLoS Med; 2024 Jun; 21(6):e1004335. PubMed ID: 38829880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.
    Zoungas S; de Galan BE; Ninomiya T; Grobbee D; Hamet P; Heller S; MacMahon S; Marre M; Neal B; Patel A; Woodward M; Chalmers J; ; Cass A; Glasziou P; Harrap S; Lisheng L; Mancia G; Pillai A; Poulter N; Perkovic V; Travert F
    Diabetes Care; 2009 Nov; 32(11):2068-74. PubMed ID: 19651921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A
    Tian J; Ohkuma T; Cooper M; Harrap S; Mancia G; Poulter N; Wang JG; Zoungas S; Woodward M; Chalmers J
    Diabetes Care; 2020 Jun; 43(6):1293-1299. PubMed ID: 32193249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.
    van der Leeuw J; Visseren FL; Woodward M; van der Graaf Y; Grobbee DE; Harrap S; Heller S; Mancia G; Marre M; Poulter N; Zoungas S; Chalmers J
    Diabetologia; 2016 Dec; 59(12):2603-2612. PubMed ID: 27586250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 10-year follow-up of intensive glucose control in type 2 diabetes.
    Holman RR; Paul SK; Bethel MA; Matthews DR; Neil HA
    N Engl J Med; 2008 Oct; 359(15):1577-89. PubMed ID: 18784090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of glycaemic control and hypoglycaemic episodes to 4-year cardiovascular outcomes in people with type 2 diabetes starting insulin.
    Freemantle N; Danchin N; Calvi-Gries F; Vincent M; Home PD
    Diabetes Obes Metab; 2016 Feb; 18(2):152-8. PubMed ID: 26511332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basal insulin and cardiovascular and other outcomes in dysglycemia.
    ; Gerstein HC; Bosch J; Dagenais GR; Díaz R; Jung H; Maggioni AP; Pogue J; Probstfield J; Ramachandran A; Riddle MC; Rydén LE; Yusuf S
    N Engl J Med; 2012 Jul; 367(4):319-28. PubMed ID: 22686416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 178.